Oncology News

The National Cancer Centre Singapore, Singapore Clinical Research Institute and IMS Health announced a collaboration to develop its first hepatocellular carcinoma registry in Asia via the Asian HCC Physician Network, in an effort to better manage patients, according to a press release.

Gadoxetic acid–enhanced MRI was accurate in the detection of portal vein thrombosis in patients with hepatocellular carcinoma, as well as for differentiating between malignant and benign portal vein thrombosis, according to published findings.

The cumulative use of several antiretrovirals, including d-drugs Zerit, Videx, Viread and Agenerase, were independently associated with increased rates of end-stage liver disease and hepatocellular carcinoma among adults with HIV.

In a retrospective study, researchers found that Chinese patients with breast cancer and hepatitis, more specifically hepatitis B virus infection, may lead to second primary hepatocellular carcinoma.

In the MORE clinical trial, the use of SIR-Spheres ytrrium-90 resin microspheres for radioembolization was safe and effective among elderly patients with unresectable liver-dominant metastatic colorectal cancer.

Delcath Systems, Inc. announced it has reached a special protocol assessment agreement with the FDA for the design of its new phase 3 FOCUS trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System for the treatment of hepatic dominant ocular melanoma.

Hospital expenditures near the end of life among older patients with cancer appeared higher in the U.S., Canada and Norway than other Western countries, according to the results of a retrospective cohort study.

Researchers in Japan found that high consumption of alcohol increased the risk for hepatocellular carcinoma among patients with fatty liver disease, according to data from a retrospective cohort study.

Patients with hepatitis C virus infection-related hepatocellular carcinoma who underwent liver transplantation were at an increased risk for developing negative outcomes, such as graft loss and reduced survival, compared with patients with HCC due to other causes, according to published findings.

SillaJen, Inc. announced it has initiated its phase 3 open-label study of Pexa-Vec and dosed its first patient with advanced hepatocellular carcinoma.